Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab subcutaneous induction for moderately to severely active Crohn's disease
NL-OMON51325Phase 3Withdrawn
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of guselkumab in Crohn's disease (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Clinical remission at Week 12 and Endoscopic response at Week 12. Planned start Feb 2022; status: withdrawn.
02
Drugs
guselkumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON51325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51325.